Trials / Completed
CompletedNCT02399813
A Phase 2 Study of Axalimogene Filolisbac (ADXS11-001) in Participants With Carcinoma of the Anorectal Canal
Phase 2 Study of ADXS11-001 in Subjects With Persistent/Recurrent, Loco-Regional or Metastatic Squamous Cell Carcinoma of the Anorectal Canal
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 36 (actual)
- Sponsor
- Advaxis, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a single arm Phase 2 study. Stage 1 and 2 of the study are monotherapy evaluations of ADXS11-001 in 31 and 24 participants, respectively with persistent/recurrent, loco-regional or metastatic squamous cell carcinoma (SCCA) of the anorectal canal that have received at least 1 regimen for the treatment of advanced disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Axalimogene filolisbac |
Timeline
- Start date
- 2016-06-02
- Primary completion
- 2019-01-03
- Completion
- 2019-01-03
- First posted
- 2015-03-26
- Last updated
- 2023-03-20
- Results posted
- 2023-03-20
Locations
10 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02399813. Inclusion in this directory is not an endorsement.